NHS
North of England secures new ‘centres of excellence’ in ‘precision medicine’
October 27, 2015Manufacturing and Production, Research and Development NHS, Northern Health Science Alliance, UK
The umbrella group formed by the leading northern universities, teaching hospitals and Academic Health Science Networks – the Northern Health …
Revealed: recommendations from the Accelerated Access Review
October 27, 2015Manufacturing and Production, Research and Development Accelarated Access Review, NHS
Ministers have been urged to introduce conditional approvals for innovative new drugs, and ‘radically new’ central agreements on drug pricing, …
NICE launches new service to speed NHS adoption of health technologies
October 13, 2015Manufacturing and Production, Research and Development, Sales and Marketing NHS, NICE, OMA, market access, office for market access
NICE is introducing a new service, the Office for Market Access (OMA), to work with industry to speed up NHS …
Simple blood test can accurately predict imminent heart attacks
October 8, 2015Research and Development NHS, heart attack
A simple blood test which predicts whether a patient suffering chest pains will have a heart attack has the potential to save …
NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment
October 7, 2015Research and Development Merck, NHS, NICE, keytruda, skin cancer
The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …
UK tops Quality of Death rankings
October 6, 2015Medical Communications NHS, ageing population, palliative care
The UK has ranked first in the 2015 Quality of Death Index, a measure of the quality of palliative care …
Why London is at the heart of life sciences
October 5, 2015Research and Development NHS
by Eliot ForsterWhatever disease you’re trying to cure, you can bet that somebody in London has it. That probably isn’t …
David Cameron pledges seven-day GP service by 2020
October 5, 2015Medical Communications NHS, david cameron
Millions of patients will benefit from ground-breaking plans for seven-day access to both their GPs and hospitals, British Prime Minister …
ABPI responds to UK medicines cost controversy
September 25, 2015Medical Communications, Sales and Marketing ABPI, Cancer Drugs Fund, NHS
Alison Clough, acting CEO of the Association of the British Pharmaceutical Industry (ABPI), has responded to recent reports in the …
NICE approves first in new class of leukaemia drugs
September 24, 2015Cancer Drugs Fund, Gilead Sciences, NHS, NICE, idelalisib, leukaemia, zydelig
NICE has issued final draft guidance which recommends that Gilead’s Zydelig should be made available on the NHS for some …
Counting the true cost of the Cancer Drugs Fund cuts
September 14, 2015Research and Development Cancer, Cancer Drugs Fund, NHS, clinical trials, cuts, oncology
Leading figures from the pharma industry and cancer charities reacted with dismay to the recent cuts to the Cancer Drugs …
Companies braced for new round of cancer cuts
September 4, 2015Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, cuts
Several treatments that extend the lives of people with cancer are expected to be removed from the Cancer Drugs Fund …
Health ministers vow NHS tech revolution
September 3, 2015Medical Communications Jeremy Hunt, NHS, data protection, digital technology, george freeman
UK health ministers have challenged the NHS to fully utilise technology, to empower patients to manage their own healthcare needs.Their …
NHS approves electronic consent technology in clinical trials
August 28, 2015Medical Communications, Research and Development Mytrus, NHS, clinical trials, digital health technology, electronic informed consent
Clinical technology and services company Mytrus has announced that its software platform for electronic informed consent has received approval for …
NHS restriction of CML treatment in England criticised
August 27, 2015Medical Communications, Sales and Marketing NHS, NICE, chronic myeloid leukaemia, leukaemia
Medical experts have criticised NHS cost regulators’ decision to limit the use of Ariad’s Iclusig (ponatinib) in the treatment of …
Latest content
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
